(HR) Healthcare Realty Trust - Overview
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NYSE (USA) | Market Cap: 7.141m USD | Total Return: 43% in 12m
Avg Turnover: 86.3M
Qual. Beats: 1
Rev. Trend: -95.6%
Qual. Beats: 0
Warnings
High Debt/EBITDA (8.4) with thin interest coverage (-0.1)
Interest Coverage Ratio -0.1 is critical
Altman Z'' -2.69 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Healthcare Realty Trust Incorporated (HR) is a Maryland-based Real Estate Investment Trust (REIT) specializing in the ownership, management, and development of medical outpatient buildings. The company focuses on properties located on or near market-leading hospital campuses, a strategy designed to capitalize on high tenant retention and referral networks inherent to healthcare ecosystems.
As of late 2025, the portfolio comprised 579 properties across 28 states, totaling 33.6 million square feet with an enterprise value of approximately $11.1 billion. The medical office building (MOB) sector generally benefits from steady demand driven by an aging population and the ongoing shift of surgical procedures from inpatient hospitals to lower-cost outpatient settings.
Investors may find ValueRay useful for evaluating the long-term dividend sustainability of this REIT. Unlike broader commercial real estate, healthcare-focused REITs often utilize triple-net or gross lease structures that provide predictable cash flows while insulating the owner from certain rising operational costs.
- Occupancy growth in outpatient buildings drives core funds from operations
- Hospital campus proximity sustains high tenant retention and pricing power
- Interest rate fluctuations impact financing costs and REIT valuation multiples
- Asset recycling and strategic dispositions influence balance sheet leverage ratios
- Healthcare employment trends dictate demand for medical office square footage
| Net Income: -201.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: -0.14% < 20% (prev -16.68%; Δ 16.54% < -1%) |
| CFO/TA 0.05 > 3% & CFO 462.2m > Net Income -201.3m |
| Net Debt (4.55b) to EBITDA (541.8m): 8.40 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (347.4m) vs 12m ago -0.60% < -2% |
| Gross Margin: -8.58% > 18% (prev -0.42%; Δ -816.1% > 0.5%) |
| Asset Turnover: 11.82% > 50% (prev 11.82%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: -0.06 > 6 (EBITDA TTM 541.8m / Interest Expense TTM 190.1m) |
| A: -0.00 (Total Current Assets 149.6m - Total Current Liabilities 151.3m) / Total Assets 9.15b |
| B: -0.50 (Retained Earnings -4.60b / Total Assets 9.15b) |
| C: -0.00 (EBIT TTM -12.0m / Avg Total Assets 9.82b) |
| D: -0.99 (Book Value of Equity -4.60b / Total Liabilities 4.65b) |
| Altman-Z'' = -2.69 = D |
| DSRI: 2.33 (Receivables 257.2m/117.8m, Revenue 1.16b/1.24b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.13 (AQ_t 0.13 / AQ_t-1 0.97) |
| SGI: 0.94 (Revenue 1.16b / 1.24b) |
| TATA: -0.07 (NI -201.3m - CFO 462.2m) / TA 9.15b) |
| Beneish M = -2.56 (Cap -4..+1) = A |
As of June 02, 2026, the stock is trading at USD 19.48 with a total of 2,004,755 shares traded.
Over the past week, the price has changed by -4.32%,
over one month by +2.41%,
over three months by +6.97% and
over the past year by +43.02%.
Healthcare Realty Trust has received a consensus analysts rating of 3.45. Therefore, it is recommended to hold HR.
- StrongBuy: 2
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.5 | 5% |
P/E Forward = 10.8342
P/S = 6.1517
P/B = 1.5893
P/EG = 8.8222
Revenue TTM = 1.16b USD
EBIT TTM = -12.0m USD
EBITDA TTM = 541.8m USD
Long Term Debt = 3.80b USD (from longTermDebt, last quarter)
Short Term Debt = 236.1m USD (from shortTermDebt, last quarter)
Debt = 4.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 236.1m
Net Debt = 4.55b USD (calculated: Debt 4.58b - CCE 26.2m)
Enterprise Value = 11.7b USD (7.14b + Debt 4.58b - CCE 26.2m)
Interest Coverage Ratio = -0.06 (Ebit TTM -12.0m / Interest Expense TTM 190.1m)
EV/FCF = 83.51x (Enterprise Value 11.7b / FCF TTM 140.0m)
FCF Yield = 1.20% (FCF TTM 140.0m / Enterprise Value 11.7b)
FCF Margin = 12.06% (FCF TTM 140.0m / Revenue TTM 1.16b)
Net Margin = -17.34% (Net Income TTM -201.3m / Revenue TTM 1.16b)
Gross Margin = -8.58% ((Revenue TTM 1.16b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 64.14% (prev -27.68%)
Tobins Q-Ratio = 1.28 (Enterprise Value 11.7b / Total Assets 9.15b)
Interest Expense / Debt = 4.15% (Interest Expense 190.1m / Debt 4.58b)
Taxrate = 21.0% (US default 21%)
NOPAT = -9.47m (EBIT -12.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.99 (Total Current Assets 149.6m / Total Current Liabilities 151.3m)
Debt / Equity = 1.03 (Debt 4.58b / totalStockholderEquity, last quarter 4.44b)
Debt / EBITDA = 8.40 (Net Debt 4.55b / EBITDA 541.8m)
Debt / FCF = 32.50 (Net Debt 4.55b / FCF TTM 140.0m)
Total Stockholder Equity = 4.64b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.05% (Net Income -201.3m / Total Assets 9.15b)
RoE = -2.18% (Net Income TTM -201.3m / Total Stockholder Equity 9.24b)
RoCE = -0.09% (EBIT -12.0m / Capital Employed (Equity 9.24b + L.T.Debt 3.80b))
RoIC = -0.10% (negative operating profit) (NOPAT -9.47m / Invested Capital 9.21b)
WACC = 5.54% (E(7.14b)/V(11.7b) * Re(6.98%) + D(4.58b)/V(11.7b) * Rd(4.15%) * (1-Tc(0.21)))
Discount Rate = 6.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -3.80%
[DCF] Terminal Value 73.10% ; FCFF base≈166.2m ; Y1≈145.8m ; Y5≈117.8m
[DCF] Fair Price = N/A (negative equity: EV 1.89b - Net Debt 4.55b = -2.66b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: -95.59 | Revenue CAGR: -5.45% | SUE: -0.29 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.03 | Chg30d=N/A | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=-0.11 | Chg30d=-22.22% | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=-5.0%
EPS next Year (2027-12-31): EPS=-0.10 | Chg30d=-66.67% | Revisions=+20% | GrowthEPS=+9.1% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +20%